Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Pfizer (PFE – Research Report) yesterday and set a price target of $45.00. The company’s shares closed yesterday at $25.89.
Chen covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Merck & Company, and Pfizer. According to TipRanks, Chen has an average return of -8.6% and a 41.18% success rate on recommended stocks.
Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $31.18, implying a 20.43% upside from current levels. In a report released on March 1, Truist Financial also assigned a Buy rating to the stock with a $27.04 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $40.15 and a one-year low of $25.38. Currently, Pfizer has an average volume of 46.82M.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PFE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfizer (PFE) Company Description:
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More on PFE:
- Cardiff Oncology doses first patient in CRDF-004 trial
- Pfizer to hold Oncology Innovation Day
- Olema Pharmaceuticals (NASDAQ:OLMA) Stock: Is There More Upside After a Remarkable Run in 2023?
- Pfizer announces top-line Abrysvo vaccine efficacy and safety data
- Pfizer files automatic mixed securities shelf
